Avadel Pharmaceuticals has successfully transitioned into a commercial-stage entity, evidenced by a 54.9% quarterly revenue growth rate as of 2025Q3 and the achievement of positive operating margins.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 2, 2026 | -$0.05-162.5% vs $0.08 | — vs $80M |
Q4 2025 Nov 4, 2025 | — vs $0.04 | $77M-3.5% vs $80M |
Q3 2025 Aug 7, 2025 | $0.10+400.0% vs $0.02 | $68M-7.4% vs $74M |
Q2 2025 May 7, 2025 | -$0.05+28.6% vs -$0.07 | $53M-9.8% vs $58M |
Benchmark AVDL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avadel Pharmaceuticals plc (AVDL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.64 | $2.1B | -42.43 | 504.79% | -28.87% | -60.44% | — | |
| $234.76 | $14.75B | -40.20 | 4.88% | 4.37% | 4.62% | — | |
| $132.37 | $6.81B | -35.97 | 65.55% | -18.18% | -189.73% | — | |
| $19.10 | $1.41B | 5.79 | 18.52% | 80.56% | 30.03% | — | |
| $26.16 | $1.52B | -38.47 | 8.63% | 7.26% | 9.29% | — | |
| $34.84 | $2.73B | 53.60 | 10.4% | 6% | 15.98% | — |
Avadel Pharmaceuticals plc (AVDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avadel Pharmaceuticals plc (AVDL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 12, 2026·SEC
Jan 20, 2026·SEC
Jan 12, 2026·SEC
Get notified when AVDL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avadel Pharmaceuticals plc (AVDL) stock FAQ — growth, dividends, profitability & financials explained
Avadel Pharmaceuticals plc (AVDL) reported $248.5M in revenue over the trailing twelve months. Revenue was $169.1M in fiscal year 2024. That is 3351% more than the $4.9M of fiscal year 1996.
Avadel Pharmaceuticals plc (AVDL) grew revenue by 504.8% in fiscal year 2024, compared with the prior fiscal year.
No. Avadel Pharmaceuticals plc (AVDL) reported a net loss of $0.3M over the trailing twelve months.
Avadel Pharmaceuticals plc (AVDL) had a return on equity (ROE) of -60.4% in fiscal year 2024. A negative ROE means the company lost money over the period.
Avadel Pharmaceuticals plc (AVDL) generated $35.4M in free cash flow over the trailing twelve months.
